How to optimise duration of antibiotic treatment in patients with sepsis?


Published in:
BMJ (Clinical research ed.)

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2020 BMJ. This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
How to optimise duration of antibiotic treatment in patients with sepsis?

TP Hellyer, T Mantle, R McMullan, P Dark

What you need to know

- Guidelines recommend 7 to 10 days of antibiotic treatment for patients with sepsis, but a shorter duration may be safe in certain individuals.
- Low quality evidence suggests that monitoring biomarkers such as procalcitonin can reduce antibiotic duration in sepsis by about one day, but the effectiveness in severe disease and in low resource settings is not known.
- Use your clinical judgement to consider the diagnostic evidence, signs of resolution or worsening of infection, and individual risk when making a decision about the choice and duration of antibiotic treatment.

Sepsis occurs when the body’s response to infection is imbalanced. It can result in life threatening organ dysfunction.1 About 49 million patients had sepsis worldwide in 2017 and 11 million people died of the condition.2 Among those hospitalised with sepsis, 17% die in hospital and a further 15% die within a year of hospital discharge.3-4

Antibiotics represent the cornerstone of treatment. The Surviving Sepsis Campaign (SSC) consensus guidelines recommend treatment for 7 to 10 days, but this is a weak recommendation.3 Use of antibiotics risks the emergence of antimicrobial resistance and antibiotic-associated infections, such as Clostridiodes difficile. Patients may suffer from toxic effects of the drugs.5 Balancing the need to treat severe infections effectively against the risks of overuse of antibiotics is central to the principle of antibiotic stewardship. For severe covid-19, antibiotic stewardship remains important for critically ill patients with pneumonia and sepsis who are commonly treated with broad spectrum antibiotics.6 Antibiotic overuse in sepsis results in substantial risk of acquiring difficult-to-treat infections, with further risk of sepsis and poor patient outcomes.5

The optimum duration of antibiotic treatment for patients with sepsis is uncertain. A biomarker-guided approach—for example, using serial measurements of procalcitonin to determine optimal duration of antibiotics—has been studied. Trials have evaluated fixed short periods of antibiotic treatment in patients with specific infections that can cause sepsis. It is uncertain whether any of these approaches can safely guide decisions in practice on the duration of antibiotic treatment for patients with sepsis.

What is the evidence of uncertainty?

Biomarker-guided antibiotic treatment

Several biomarkers have been investigated in sepsis, but our search only identified procalcitonin and C reactive protein as biomarkers used to alter duration of antibiotic treatment. High quality evidence is lacking to recommend the routine use of procalcitonin-guided antibiotic treatment decisions for adult patients with sepsis. Table 1 (supplementary files) provides a summary of the evidence. Studies do not report longer-term patient outcomes from sepsis, and evidence for the cost-effectiveness of biomarker-guided antibiotic treatment duration is lacking.8

Measuring circulating procalcitonin is seen to reduce antibiotic duration by about one day (9.3 versus 10.4 days)8,10 and results in a lower 30 day mortality (odds ratio 0.89, 95% confidence interval 0.80 to 0.99) in patients with sepsis and those with respiratory tract infections, as per meta-analyses.9,10 These durations are not particularly short and reductions in duration were not observed in the sickest patients. The quality of evidence is low, as most trials do not provide details on standards of care and are at high risk of bias.8,9 Trials had different algorithms, which used daily or intermittent procalcitonin measurement, and one trial had a single measurement.9

One trial (97 patients) in Brazil evaluated C reactive protein in patients with suspected or confirmed sepsis in intensive care units and found no difference in antibiotic duration between approaches guided by procalcitonin or C reactive protein.11

Sources and search selection

We searched Medline and Embase from inception to 16 October 2019. We searched for randomised controlled trials and systematic reviews of biomarker-guided or fixed durations of antibiotic treatment compared with standard care for adult patients with sepsis. We used terms such as “sepsis”, “bacterial infections”, “bacteraemia”, “anti-bacterial agents”, “protein precursors”, “duration”, and variations on these terms. We also included studies that investigated specific infections that commonly cause sepsis. The three commonest infection sources of sepsis are respiratory tract, urinary tract, and intra-abdominal infections, as found in the National Confidential Enquiry into Patient Outcome and Death 2015 Sepsis report. Twenty eight randomised controlled trials and 29 systematic reviews or meta-analyses were considered (supplementary files 1, 2). References were checked for other relevant articles not retrieved in the search. Two further randomised controlled trial studies were published in 2020 (supplementary files, table 1). To provide a concise narrative review, we selected up-to-date meta-analyses and key trials that addressed antibiotic treatment duration in sepsis and in major infections that cause sepsis (tables 1, 2, supplementary files).

1 Newcastle University, Newcastle, UK
2 Manchester Medical School, Manchester, UK
3 Belfast Health & Social Care Trust and Reader, Centre for Experimental Medicine, Queen’s University Belfast, Belfast, UK
4 Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, UK
5 Northern Care Alliance NHS Group, Greater Manchester, UK

Correspondence to
paul.m.dark@manchester.ac.uk

Cite this as: BMJ 2020;371:m4357
http://dx.doi.org/10.1136/bmj.m4357

Published: 23 November 2020
No trials have been completed in the UK and few trials have been conducted in low and middle income countries. Most patients with sepsis live in low and middle income countries. It is uncertain whether these findings can be realised in all healthcare systems, particularly in low resource settings.

**Fixed short duration of antibiotic treatment**

Respiratory tract infections, urinary tract infections, and intra-abdominal infections are the commonest infection sources of sepsis. The duration of antibiotic treatment differs depending on the source of infection. Evidence from trials suggests that five days of antibiotics for community acquired pneumonia, seven days or fewer for urinary tract infections, and four days for intra-abdominal infections with source control have effectiveness comparable with longer duration of antibiotics over 10-14 days. Patients who require critical care support are generally excluded from these trials. High quality evidence is lacking for high severity and high risk groups, where longer durations may be required until clinical stability is reached.

**Is ongoing research likely to provide relevant evidence?**

We searched Clinicaltrials.gov and the ISRCTN registry and identified five ongoing trials (Box 1). Three trials compare fixed duration treatments and will add to the evidence on the effectiveness and safety of short term antibiotic duration. One trial is investigating whether a diagnostic bundle could reduce antibiotic use safely. We are conducting a double-blinded trial (ADAPT-Sepsis) that will provide evidence on the clinical and cost effectiveness of biomarker-guided antibiotic duration in UK healthcare settings, and which has recently been extended to include patients with covid-19 and sepsis as part of the UK’s portfolio of urgent public health research during the pandemic. Evidence on long term clinical outcomes is lacking. The ADAPT-Sepsis trial will help address this using linked national healthcare digital patient records, and the SAB7 trial will address this with in-trial follow-up until 6 months.

**Box 1: Ongoing trials on optimising antibiotic treatment in patients with sepsis**

- ADAPT-Sepsis will determine the utility of C reactive protein and procalcitonin to reduce antibiotic use in patients with suspected sepsis in UK critical care units. ISRCTN7473244.
- The BALANCE trial will determine whether seven days of adequate antibiotic treatment is non-inferior to 14 days of treatment for critically ill patients with bacteraemia. NCT03005145.
- The SAB7 trial will determine whether seven days of antibiotics is non-inferior to 14 days of antibiotics for patients with uncomplicated *Staphylococcus aureus* bacteraemia. NCT03514446.
- A trial comparing five days with 10 days of antibiotic treatment for patients with presumed infections. NCT02899143.
- The PIBCAP trial will compare the utility of a pneumonia investigation bundle, including multiplex real-time polymerase chain reaction assays, with investigation and treatment as per guidelines from the National Institute for Health and Care Excellence. Primary outcome will assess clinical response and antibiotic use (defined daily dose). ISRCTN42850134.

**What should we do in light of the uncertainty?**

Antibiotic treatment duration could be safely shortened for patients with sepsis, but other factors must be considered, including the site of infection and severity. For example, the SSC guidelines state that shorter antibiotic courses may be appropriate for patients with rapid clinical resolution following effective source control of intra-abdominal or urinary sepsis and those with anatomically uncomplicated pyelonephritis (weak recommendations, low quality of evidence). Control of the source of infection (by surgical or radiological means) is important, particularly for intra-abdominal infections. Some pathogens, such as non-fermenting Gram-negative bacilli, may require prolonged antibiotic treatment to avoid relapse of infection.

Patients with sepsis have multiple morbidities and require complex care. Other uncertainties pertaining to antibiotic treatment in sepsis include choice of antibiotic, dosing, starting and stopping treatment, and considerations in patients with complications such as shock or organ failure. The clinical multidisciplinary team must weigh up diagnostic evidence, signs of resolution or worsening of infection, and individual risk in the context of patient choice. We suggest following the principles of antibiotic stewardship in the context of clinical judgement by identifying and controlling the infectious source, as well as narrowing, and subsequently discontinuing, antibiotics as soon as laboratory, radiological, and clinical parameters permit.

### Education into practice

- What factors do you consider when deciding the duration of antibiotic treatment in a patient?
- How do you use laboratory results from microbiology sampling, biomarkers, and routine blood tests in your initial suspicion of infection or to alter decisions on antibiotic duration?
- When delivering urgent empirical antibiotics for sepsis, what is your antibiotic stewardship plan?

### Recommendations for future research

Future research should determine the optimal duration of antibiotic treatment in patients in whom antibiotic exposure can be prolonged owing to severe disease, and in those who require organ support.

- Population: Patients with sepsis who require critical care organ support
- Intervention: Short duration antibiotics
- Comparator: Standard practice
- Non-inferior clinical outcomes: Antibiotic use (duration, defined daily dose), mortality, duration of organ support

### What patients need to know

- Sepsis is a life threatening condition and appropriate antibiotics are needed urgently to treat infection. Guidelines recommend 7 to 10 days of antibiotics but the evidence for this is of low quality
- Optimising the duration of antibiotic treatment is important to reduce harms such as antibiotic resistance and antibiotic associated infections
- Measuring certain biomarkers in blood has been shown safely to reduce duration of antibiotic treatment by about a day, but this evidence is of low quality. Fixed short duration of antibiotics is also shown to be safe in certain infections that can lead to sepsis
- We don’t know if these approaches are safe in patients with severe disease or those requiring intensive care, and in low resource settings
- Ongoing research aims at delivering shorter, safer courses of antibiotic treatment for patients with sepsis

### How patients were involved in the creation of this article

Patients were not directly involved in the writing of this article. We are conducting the ADAPT-Sepsis trial and our study team includes members of the Intensive Care Society’s Patients and Relatives group and the
Manchester NIHR Biomedical Research Centre’s Patient and Public Involvement and Engagement group. We are engaging with these groups to guide the design, delivery, and communication of our research.

Competing interests: Tom Hellyer is supported by the National Institute for Health Research (NIHR) as an academic clinical lecturer and Paul Dark is supported by the Manchester NIHR Biomedical Research Centre. Paul Dark is on the clinical advisory board of DNA Electronics delegated by Salford Royal NHS Trust to advise on clinical applications and safety of rapid diagnostic technology for bloodstream infections. Ronan McMillan is involved in research with Randox Ltd for a point-of-care test in sepsis funded by a grant from Innovate UK. He has given lectures on fungal infections at educational meetings sponsored by Gilead.

Provenance and peer review: commissioned; externally peer reviewed.


